Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.

Inclusion Criteria: * Body mass index between 18.0 to 30.0 kg/m2. * Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. * Non-pregnant woman (negative pregnancy test) and not currently breast feeding * Female subjects abstain from either hormonal methods of contraception * Male subjects who are willing or able to use effective contraceptive * Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study. Exclusion Criteria: * History serious hypersensitivity reactions * History or evidence of clinically significant diseases or any significant ongoing chronic medical illness * History or evidence of family diabetes * History or evidence of type 1 diabetes mellitus, diabetic ketoacidosis, diabetic pre-coma * History or evidence of shock or severe dehydrate or severe infection * History or evidence of preceding diarrhea or vomiting within 24 hours prior to admission in each period * History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse * History of problems with swallowing tablet or capsule * History of sensitivity to heparin or heparin-induced thrombocytopenia * Any condition possibly affecting drug absorption * Have renal creatinine clearance (Clcr) \< 45 mL/min based on serum creatinine results at the screening laboratory test * 12-lead ECG demonstrating QTc \>450 msec, a QRS interval \>120 msec or with an abnormality considered clinically significant at screening